As we continue to push boundaries in #ADC research, we are honored to be awarded the Best Clinical Publication at this year’s World ADC Event Series in San Diego. Congratulations to the SORAYA clinical team for their research. Learn more about our efforts in cancer research: https://bit.ly/4eqSh7d
AbbVie
Fabricación de productos farmacéuticos
North Chicago, Illinois 1.456.386 seguidores
Sobre nosotros
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 26,000+ people worldwide and markets medicines in more than 170+ countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter and like us on Facebook.
- Sitio web
-
http://www.abbvie.com
Enlace externo para AbbVie
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- North Chicago, Illinois
- Tipo
- Empresa pública
- Especialidades
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics y Eye Care
Ubicaciones
Empleados en AbbVie
Actualizaciones
-
Oyewale Daejin Abidoye, our VP, therapeutic area head, solid tumor, explains the need to improve clinical practices for #biomarker testing in non-small cell lung cancer (#NSCLC). Health care disparities continue to exist in biomarker testing, especially for those in socially disadvantaged communities. Read his latest article to learn more. #LungCancerAwarenessMonth https://lnkd.in/gzg9uFv9
Improving clinical practices for biomarker testing is important to inform treatment approaches for patients with non-small cell lung cancer (#NSCLC), especially for those in underserved communities. Here are my thoughts on the importance of addressing this unmet need. #LungCancerAwarenessMonth #LCAM
-
Hear members of our #Veterans employee resource group discuss their connection to the #VeteransDay theme: legacy to loyalty and service. Learn more about our support for veterans and how they impact our workplace: https://bit.ly/3AFdXPf #BelongAtAbbVie [Video description: Members of the AbbVie Veterans Employee Resource Group share what living with a legacy to loyalty and service means to them.]
-
Genetic medicines have the potential to revolutionize patient care. But how do they work? Learn more in a Q&A with Clark Pan, our VP of biotherapeutics and genetic medicine technologies, and discover how we’re using #GeneticMedicine technologies and platforms to find treatments for patients: https://lnkd.in/g9pUGR7f [Image description: A series of illustrations depicting how genetic medicine works once entered in the body via a vector.]
-
ICYMI: Members of our executive leadership team discussed our Q3 2024 #FinancialResults during this week’s #earnings call. Swipe to learn more about our performance from our leaders. $ABBV [Image description: Members of AbbVie’s executive leadership team share their remarks on our Q3 2024 Financial Results, including: Robert A. Michael, Jeffrey R. Stewart, Carrie Strom, Roopal Thakkar and Scott T. Reents.]
-
The Ways We Work are the five pillars at the foundation of our culture guiding how our employees innovate and collaborate. Throughout October, employees worldwide participated in our annual Celebration of Culture, where they recognized how their individual actions enable us to make a real difference in people’s lives – while also making us a great place to work. Learn more: https://bit.ly/4hsDTOE #AbbVieLife
-
-
Wishing a sincere Shubh Deepavali to all who are celebrating the start of #Diwali, the Festival of Lights. #BelongAtAbbVie [Video description: Imagery showing Diwali celebrations including sparklers, lights and lanterns, and candles.]
-
NEWS: Today we announced a collaboration and option-to-license agreement with EvolveImmune Therapeutics to develop novel multispecific therapeutic antibodies for solid and hematologic malignancies. Learn more: https://bit.ly/4frlfVv #oncology #cancer [Video description: On-screen text reads, "Oncology News."]
-
"We delivered another quarter of strong commercial execution and significant pipeline progress. Based upon the momentum of AbbVie's business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend," said Rob Michael, our CEO. Learn more about our Q3 2024 #FinancialResults: https://abbv.ie/1e204b $ABBV #earnings [Image description: Summary of AbbVie's Q3 2024 Financial Results, including Raised 2024 Adjusted Diluted EPS Guidance Range, Quarterly Dividend Growth, Adjusted R&D Investment and Net Revenues by Therapeutic Area.]
-
Today on #WorldPsoriasisDay, we are reminded that psoriatic disease not only impacts the patient, but also their loved ones, including families, partners and caregivers. Through ongoing research and dedication to immune-mediated skin diseases, like psoriasis, we strive to meet patient needs and support the community globally. IFPA's report highlights the full impact of psoriasis: https://bit.ly/4hkWKLr [Video description: Vassilis Stakias, Global TA Lead, Dermatology, Global Medical Affairs, AbbVie, says, “Everyday, we prioritize the needs of the patients living with psoriatic disease, so they can feel free in their own skin. This World Psoriasis Day, we also support and recognize how psoriatic disease can impact those beyond the patient in solidarity with the dermatology community.”]
Páginas asociadas
Páginas similares
Acciones
ABBV
NYSE
20 minutos de retraso
171,09 US$
-3,34 (-1,915 %)
- Apertura
- 176,01
- Mínimo
- 171,03
- Máximo
- 176,63
Datos de Refinitiv
Consulta más información enFinanciación
AbbVie
2 rondas en total
Ver más información en Crunchbase
Última ronda
Deuda tras OPV
Enlace externo a Crunchbase para la última ronda de financiación
15.000.000.000,00 US$